Released Aug 3, 2016, after the close
10-Q filed Aug 4, 2016, 35 days after period end · 0001493152-16-011963
Q2 2016 · 10-Q
Revenue$5.41M$5.41M −12.7% vs Q2 2015−1.4% vs Q1 2016
Net Income-$850.00K-$850.00K N/M vs Q2 2015N/M vs Q1 2016
EPS Diluted-$0.46-$0.46 N/M vs Q2 2015N/M vs Q1 2016
Operating Income-$696,000N/M
Operating Cash Flowderived$517,000N/M
Free Cash Flowderived$403,000N/M
Margins · derived
Operating margin-12.9%+27.0 pt vs Q2 2015
Net margin-15.7%+26.7 pt vs Q2 2015
What the release said
The release
Same quarter
| Metric | Q2 2016 | Q2 2015 | Q2 2014 | Q2 2013 |
|---|---|---|---|---|
| Revenue | $5.41M | $6.19M | $6.87M | $5.53M |
| Net Income | -$850.00K | -$2.63M | -$1.35M | -$99.00K |
| EPS Diluted | -$0.46 | -$1.43 | -$0.02 | $0.00 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Ernexa Therapeutics Inc. · CIK 748592 · Engraved from SEC EDGAR